Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 8, 2001, Pages 870-879

  Iuliucci, J D ^a   Oliver, S D ^a   Morley, S ^a   Ward, C ^a   Ward, J ^a   Dalgarno, D ^a   Clackson, T ^a   Berger, H J ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 1903; FK 506 BINDING PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AREA UNDER CURVE; CROSS-LINKING REAGENTS; ELECTROCARDIOGRAPHY; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; ORGANIC CHEMICALS; SINGLE-BLIND METHOD;

EID: 0034919257     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010771     Document Type: Article

References (19)

1. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia; impact of HLA class II matching
2. Immunotherapy after bone marrow transplantation
3. Marrow transplantation for the treatment of chronic myelogenous leukemia
4. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: Importance of a graft-versus-leukemia effect
5. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse
6. Graft-versus-myeloid leukemia response following syngeneic and allogeneic bone marrow transplantation
7. Graft-versus host disease
8. Treatment of bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: A prospective, randomized, double-blind study
9. Donor leukocytes transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
10. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
11. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
12. Salvage immunotherapy using donor leukocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose
13. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization
14. Redesigning an FKBP-log and interface to generate chemical dimerizers with novel specificity
15. Cell surface tagging and a suicide mechanism in a single chimeric human protein
16. A humanized Fas receptor-based suicide switch expressed in human T lymphocytes for the induction of controlled graft-versus-leukemia
17. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
18. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus leukemia: Clinical follow-up and improved new vectors
19. Long term follow-up in 30 patients receiving HSV-tk transduced donor lymphocytes after allo-BMT